Ellsworth Advisors LLC bought a new stake in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 11,984 shares of the medical equipment provider's stock, valued at approximately $629,000. Ellsworth Advisors LLC owned 0.09% of iRadimed as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of the stock. Jump Financial LLC raised its position in shares of iRadimed by 4.9% during the 1st quarter. Jump Financial LLC now owns 4,300 shares of the medical equipment provider's stock worth $226,000 after purchasing an additional 200 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of iRadimed by 4.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,577 shares of the medical equipment provider's stock worth $252,000 after purchasing an additional 204 shares during the last quarter. First Horizon Advisors Inc. boosted its position in iRadimed by 78.7% during the first quarter. First Horizon Advisors Inc. now owns 513 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 226 shares during the last quarter. Martingale Asset Management L P boosted its position in iRadimed by 2.4% during the first quarter. Martingale Asset Management L P now owns 12,831 shares of the medical equipment provider's stock worth $673,000 after acquiring an additional 300 shares during the last quarter. Finally, State of Wyoming boosted its position in iRadimed by 11.3% during the first quarter. State of Wyoming now owns 3,013 shares of the medical equipment provider's stock worth $158,000 after acquiring an additional 307 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company's stock.
iRadimed Price Performance
IRMD traded up $0.03 on Wednesday, reaching $71.49. 6,187 shares of the company's stock were exchanged, compared to its average volume of 44,133. The stock has a market cap of $909.39 million, a PE ratio of 44.16 and a beta of 1.02. iRadimed Corporation has a twelve month low of $46.86 and a twelve month high of $74.43. The stock's fifty day moving average price is $66.57 and its 200-day moving average price is $58.72.
iRadimed Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Thursday, August 28th. Shareholders of record on Monday, August 18th were given a $0.17 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $0.68 dividend on an annualized basis and a yield of 1.0%. iRadimed's dividend payout ratio is presently 41.98%.
Insider Buying and Selling
In other iRadimed news, Director Monty K. Allen sold 1,102 shares of the company's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $69.10, for a total value of $76,148.20. Following the transaction, the director owned 19,898 shares of the company's stock, valued at $1,374,951.80. This represents a 5.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 36.80% of the stock is owned by insiders.
iRadimed Company Profile
(
Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Featured Stories

Before you consider iRadimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRadimed wasn't on the list.
While iRadimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.